Navigation Links
Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
Date:10/27/2011

rnal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business.  Analysts and investors frequently ask us for this information.  We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

Our non-GAAP operating loss during the three months ended September 30, 2011 and 2010 was approximately $837,000 and $591,000, respectively.  Our non-GAAP operating loss during the six months ended September 30, 2011 and 2010 was approximately $1.8 million and $1.2 million, respectively.  The increase in non-GAAP operating loss is attributed primarily to the increase in Selling and Marketing expenses.Expense AdjustmentsThree-Months EndedGAAPShare-based
ExpenseDepreciationAmortizationNon-GAAPSeptember 30, 2011Gross Profit

$4,208,000

$6,000

$8,000$4,222,000% of sales

84.7%85.0%Operating ExpensesGeneral and administrative

942,000

(90,000)

(40,000)812,000Research and development

457,000

(11,000)

(3,000)443,000Selling and marketing

3,870,000

(53,000)

(13,000)3,804,000Amortization

214,000$(214,000)

-5,483,000

(154,000)

(56,000)

(214,000)

5,059,000Operating Loss

$(1,275,000)

$160,000

$64,000

$214,000

$(837,000)September 30, 2010Gross Profit

$2,650,000

$4,000

$16,000$2,670,000% of sales

81.7%82.3%Operating ExpensesGeneral and administrative

897,000

(43,000)

(38,000)816,000Research and development

472,000

(7,000)

(2,000)463,000Selling and marketing

2,017,000

(18,000)

(17,000)1,982,000
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Uroplasty to Issue Second Quarter 2012 Financial Results on October 27, 2011
2. Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference
3. Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012
4. Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011
5. Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
6. Uroplasty on Preliminary List of Additions to Russell 3000® and Russell Global® Indexes
7. Uroplastys Dave Kaysen to Ring NASDAQ Closing Bell
8. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
9. Uroplasty to Present at the JMP Securities Research Conference
10. Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
11. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... a leader in the pharmaceutical treatment of breathing-control disorders, ... Thomas J. Dietz, Ph.D., as the company,s chairman.  Dr. ... a diversified financial-holdings and services company.   ... and a director of Pacific Growth Equities, LLC, a ...
... YORK, Oct. 26, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging The ... are continuing to grow in significance as ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:1/22/2015)... January 23, 2015 Angelweddingdress is a famous ... invites its customers to follow it on Facebook, Twitter, and ... Valentine’s Day gift. Angelweddingdress draws a lottery every week. , ... to Feb. 28, 2015. Click Angelweddingdress homepage for ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently ... View website of AngelWeddingDress.com to find more details. ... online for a bridal party. AngelWeddingDress offers a variety ... Its maternity wedding dresses are specially designed for 2015. ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... January 22, 2015 For over 20 years, Dr. ... Oceanside and Vista area has treated just about every type ... injury circumstances. And for those same twenty-plus years, the team ... all those injuries with the best possible doctor. With ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... used to help reduce adverse events associated with nicotine ... smokers admitted to// the intensive care unit (ICU). In ... annual international scientific assembly of the American College of ... the ICU who received nicotine replacement therapy (NRT) during ...
... who have just suffered their first ischemic stroke, a ... biomarkers in their blood // that indicate their likelihood ... dying, according to Columbia University Medical Center researchers at ... of Internal Medicine, results of the new study indicate ...
... back on salt to reduce heart disease risk. The other ... for many people. Which is correct? There isn’t a simple ... (the problematic component of salt) in the diet lowers blood ... his or her genes, age, and medical conditions, reports the ...
... have identified a naturally occurring enzyme that can break ... of Alzheimer's disease.// The finding may provide researchers with ... brains of Alzheimer's patients and could one day help ... School of Medicine in St. Louis showed earlier this ...
... in the January 2007 issue of the Pediatric Blood ... vital developments in healthcare between industrialized and developing countries, ... ,Pediatric oncology has witnessed path ... the last several decades, but developing nations still have ...
... medical condition in which the victims unintentionally demand, or ... and researchers// confused. ,Research into this condition ... of awkwardness in admitting it. This disorder usually causes ... so far. ,Several researchers believe sexsomania to ...
Cached Medicine News:Health News:Smoking Cessation Therapy May be Harmful for ICU Patients 2Health News:Blood Markers Predict Risk for Recurrent Stroke and Mortality 2Health News:Naturally Occurring Enzyme Can Break Down Key Part of Alzheimer's Plaques 2Health News:Videoconferencing, an impetus to Pediatric Oncology 2
... Safely And Easily Cut Foldable Silicone ... To Cut And Remove Even High ... One Instrument.,New Miniaturized Profile Allows Insertion ... Explantation Of A Silicone Lens.,Available For ...
... Unit, Shaped Like A Fan, And Enable The ... Incision. The Gauges Start At A Width Of ... With 100-Micron Increments. The Gauges Are Easy ... The Preoperative And Postoperative Incision Result. Reusable, Autoclaveable, ...
... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture.,Open And Close With ... To The Globe During Clear Corneal ...
... A Micrometer Handle, Designed To Dial An ... Single Footplate Allows Maximum Visibility, With Titanium ... Blade Tracks Better In Tissue, And Can ... Making A Paracentesis., ,Reusable, Autoclaveable, Made In The ...
Medicine Products: